Skip to main content
. 2019 Dec 9;24(24):4505. doi: 10.3390/molecules24244505

Table 1.

Inhibitory effects of synthetic compounds on the growth of different types of human cancer cells and normal mammary epithelial cells.

Comp. Antiproliferative Activity IC50 ± SEM (µM)
HeLa[a] Hep G2[b] MCF-7[c] FaDu[d] A549[e] MCF 10A[f] SI[g]
6a >100 >100 >100 >100 >100 90.29 ± 3.41 NCh
6b >100 >100 >100 >100 >100 >100 NCh
6c >100 >100 >100 >100 >100 >100 NCh
6d >100 >100 >100 >100 >100 >100 NCh
6e 62.67 ± 4.19 50.77 ± 1.35 66.36 ± 0.05 49.50 ± 1.61 >100 85.44 ± 2.28 1.73
6f 10.16 ± 0.55 10.72 ± 0.22 20.83 ± 0.14 10.94 ± 0.12 20.05 ± 0.41 12.97 ± 0.55 1.19
6g 7.89 ± 0.86 9.62 ± 0.11 9.83 ± 0.17 6.80 ± 0.05 9.23 ± 0.16 6.57 ± 0.30 0.97
6h >100 >100 >100 >100 >100 >100 NCh
6i >100 >100 >100 >100 >100 >100 NCh
8a >100 >100 >100 >100 >100 >100 NCh
8b >100 >100 >100 >100 >100 >100 NCh
8c >100 >100 >100 80.41 ± 1.36 >100 46.59 ± 0.65 NCh
8d 3.31 ± 0.14 >20 0.480 ± 0.003 0.11 ± 0.03 6.35 ± 0.05 2.69 ± 0.46 24.45
8e 1.42 ± 0.71 >20 0.037 ± 0.001 0.00136 ± 0.00035 1.05 ± 0.05 0.047 ± 0.008 34.56
8f 4.96 ± 1.62 >20 0.158 ± 0.009 0.174 ± 0.010 2.46 ± 0.05 0.051 ± 0.021 0.29
9e >100 >100 >100 0.054 ± 0.002 11.27 ± 0.81 >100 >1851.85
10e >100 >100 >100 0.25 ± 0.02 2.94 ± 0.25 38.60 ± 2.48 154.40
11e >100 >100 >100 0.50 ± 0.06 64.30 ± 3.46 80.54 ± 7.60 161.08
12e >100 >100 >100 1.33 ± 0.07 8.77 ± 0.47 >100 >75.19
13e >100 >100 >100 48.31 ± 3.17 >100 >100 >2.07
14e >100 97.75 ± 1.55 >100 6.33 ± 0.65 44.37 ± 0.29 19.82 ± 1.41 3.13
15e 37.74 ± 4.32 26.34 ± 5.36 21.48 ± 1.47 8.85 ± 0.45 23.08 ± 0.12 54.65 ± 5.92 6.18
16e >100 >100 >100 88.11 ± 1.37 >100 >100 NCh
17e >20 >20 >20 0.236 ± 0.005 >20 >20 >84.75
18e >20 >20 >20 0.697 ± 0.021 >20 >20 >28.69
19e >20 >20 >20 8.74 ± 0.44 >20 >20 >2.29
20e >20 >20 >20 >20 >20 >20 NCh
21e >20 >20 >20 0.665 ± 0.028 >20 >20 >30.08
22e >20 >20 >20 0.020 ± 0.002 >20 >20 >1000
23e >20 >20 >20 0.638 ± 0.089 >20 >20 >31.35
24e >20 >20 >20 5.296 ± 0.366 >20 >20 >3.78
25e >20 >20 >20 0.056 ± 0.016 >20 >20 >357.14
26e >20 >20 >20 >20 >20 >20 NCh
27e >20 >20 >20 4.621 ± 0.539 >20 >20 >4.33
28e >20 >20 >20 >20 >20 >20 NCh
29e >20 >20 >20 5.067 ± 0.461 >20 >20 >3.95
30e >20 >20 >20 >20 >20 >20 NCh
31e >20 >20 >20 5.594 ± 0.628 >20 >20 >3.58
32e >20 >20 >20 >20 >20 >20 NCh
33e >20 >20 >20 10.393 ± 0.949 >20 >20 >1.92
34e >20 >20 >20 5.853 ± 0.408 >20 >20 >3.42
35e >20 >20 >20 >20 >20 >20 NCh
9d >20 >20 >20 1.054 ± 0.091 >20 >20 >18.98
9f >20 >20 >20 0.027 ± 0.002 >20 >20 >740.74
9g >20 >20 >20 >20 >20 >20 NCh
9h >20 >20 >20 >20 >20 >20 NCh
9i >20 >20 >20 >20 >20 >20 NCh
9j >20 >20 >20 >20 >20 >20 NCh
9k >20 >20 >20 4.447 ± 0.208 >20 >20 >4.50
9l >20 >20 >20 >20 >20 >20 NCh
9m >20 >20 >20 >20 >20 >20 NCh
TMP >100 >100 >100 >100 >100 >100 NCh
DOX 11.39 ± 0.48 28.04 ± 1.09 6 ± 0.07 1.27 ± 0.13 >100 0.55 ± 0.03 0.43

[a] HeLa (cervical cancer cell line); [b] Hep G2 (hepatocarcinoma cell line); [c] MCF-7 (breast cancer cell line); [d] FaDu (head and neck squamous carcinoma cell line); [e] A549 (epithelial cancer cell line); [f] MCF 10A (normal mammary epithelial cell); [g] SI: selectivity index. It was calculated as: SI = IC50 (MCF 10A)/IC50 (FaDu); [h] NC: not calculated.